PepGen (PEPG) Stock Analysis

What PepGen does

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Key metrics

ETFs linked to PEPG

Broad-market and Healthcare sector ETFs an investor holding PepGen is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PEPG fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for PepGen?

PepGen trades under the ticker PEPG on NASDAQ.

Which exchange is PEPG listed on?

PEPG is listed on NASDAQ.

What sector does PepGen operate in?

PepGen is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PEPG in a portfolio?

PortView shows PEPG's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.